Preoperative rIL-2 treatment in renal cancer: Early and late effects on lymphocyte subsets and proliferation, NK activity, IL-6 in vivo and in vitro production

International Journal of Immunotherapy

Volumn 13, Issue 1-2, 1997, Pages 33-44

  Morgia, G ^a   Mazzarino, C ^a   Monte, V ^a   Zammataro, N ^a   Napolitano, M G ^a   Stagno, F ^a   Motta, M ^a   Saita, A ^a   Giammusso, B ^a   Malaponte, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD57 ANTIGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; KIDNEY CANCER; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; NATURAL KILLER CELL; PREOPERATIVE TREATMENT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 7144227289     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Giuliani L , Giberti C , Martorana G., Rovida S Radical extensive surgery of renal cell carcinoma Long term results and prognostic faciors J Urol 143. 68, 1990
2. McNichols D W., Segura J.W, De Wurd J.H. Renal cell carcinoma, long term survival and late recurrence J. Urol., 126, 17, 1981.
3. Skinner D G , Calvin R.B., Vermillion C.D. Diagnosis and management of renal cell carcinoma A clinical and pathologic study of 309 cases. Cancer, 28, 1165, 1971.
4. Gastl G.A., Abrams J.S., Nanus D.M., Oosterkamp R., Silver J., Liu F., Chen M. Interleukin-10 production by human carcinoma cell lines and its relationship to Interleukin-6 expression. Int. J. Cancer, 55, 96, 1993.
5. Oliver R D T, Nethershell A.B.W., Battamley J.M. Unexplained spontaneous regression and alpha-IFN as treatment for merastatic renal cell carcinoma. Br J. Urol, 63, 2128, 1989.
6. Hellstrom J., Hellstrom K., Sjogren H., Warner G. Demonstration of cell-mediated immunity in human neoplasms of various histological types Int. J. Cancer, 7, 1, 1971.
7. Tsavaris N , Baxevanis C , Kosmidis P, Papamichael M The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer treated with IFN-a. Cancer Immunol Immunother, 43, 94, 1996.
8. Koo A.S., Armstrong K., Bochner B., Shimabukuro T., Tso C L , deKernion J B , Belldegrun A. Interleukin-6 and renal cell cancer production, regulation and growth effects Cancer Immunol. Immunother., 35, 97, 1992
9. Blay J Y , Schemann S., Favrot M. Local production of interleukin-6 by renal adenocarcinoma in vivo J Natl Cancer Inst., 86(3), 238, 1994
10. Bancewicz J., Aileen C.G , Lindop G The immunosuppressive effect of surgery. Br J. Surg., 60, 314, 1973
11. Lennard TW Shenton B K., Borzotta A., Donnely P.K., Taylor R M. R., The influence of surgical operation on components of the human immune system. Br. J. Surg., 72, 771, 1985
12. Brivio F, Lissoni P. Barni S , et al. Effects of a preoperative course of IL-2 on surgical end immunobiological variables in patients with colorectal cancer a phase II study Eur. J. Surg., 159, 43, 1993
13. Eggermont A M , Steiler E.P., Sugarbaker PH Laparotomy enhances intraperitoneal growth and abrogates the antitumor effect of interfeukin-2 and lymphokine-activated killer cells Surgery, 102, 71, 1987
14. Smith KA Interleukin-2: inception, impact and implication Science 240, 1169. 1988
15. Brivio F, Perego P, Zanandrea G , et al Interleuchina-2 e chirurgia maggiore quali relazion? Chirurgia, 6, 391. 1993.
16. Lissoni P, Viviani S , Santoro A. Serum levels of Interleukin-2 in cancer patients preliminary considerations. Int J Biol , 4, 203, 1989
17. Wustrow T P U , Kabelitz D IL-2 release from lymohocytes of patients with head and neck cancer Acta Otol Laryngol., 96, 179, 1989
18. Monson J.R.T., Ramsden C Guillou P J Decreased IL-2 production in patients with gastrointestinal cancer Br. J. Surg , 73. 483 1986
19. Hart I R immune profile in merastasis Curr Opin Immunol , 1, 900, 1989
20. Brivio F, Lissoni P, Tisi E., et al. Effect of preoperative IL-2 on surgery-induced lymphocytopenia in cancer patients. Oncology, 49, 215, 1992.
21. Nichols P., Ramsden C., Ward U. Penoperative immunotherapy with recombinant IL-2 in patients undergoing surgery for colorectal cancer. Cancer Res., 52(Oct.15), 5765, 1992.
22. Brivio F., Lissoni P., Alden G., Barni S., Lavorato F, Fumagalli L. Preoperative IL-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology, 53, 263, 1996.
23. Yoshino I., Yano T, Murata M. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell derived factors. Cancer Res., 52 (Feb. 15), 775, 1992.
24. Gorschluter M., Bohlen H., Hasenclever D , et al. Serum Cytokine levels correlates with clinical parameters in Hodgkin's disease. Ann Oncology, 6, 477, 1995
25. Huang M., Wang J , Lee P., et al. Human NSCLC express a type 2 cytokine pattern. Cancer Res., 55 (Sept. 1), 3847, 1995.
26. Katsumata N , Eguchi K , Fukuda M. Serum levels of cytokines in patients with untreated lung cancer. Clin Cancer Res., 2, 553, 1996.
27. Schleibenbogen C., Mohler B., Haefele J. Serum IL-8 is elevated in patients with metastatic melanoma and correlates with tumor load. Melanoma Res., 5, 179, 1995.
28. Seymour J.F, Talpaz M., Cabanillas F, et al. Serum IL-6 levels correlate with prognosis in diffuse large cell lymphoma. J. Clin One., 13(3)(March), 575, 1995.
29. Sosman J.A, Hank J A., Sondel P M., In vivo activation of lymphokine-activated killer activity with Interleukin-2; prospects for combination therapies. Semin. Oncol., 17(suppl. 1), 22, 1990.
30. Blay J.Y., Negrier S., Combaret V. Serum levels of IL-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res , 52, 3317, 1992.
31. Boyum A., Separation of leukocytes from blood and bone marrow. Scand. J. Lab. Clin. Invest., 21(suppl. 97), 31, 1968.
32. Culotta F., Peri G , Villa A., Mantovani A Rapid killing of actinomycin D treated tumor cells by human mononuclear cells. Effectors belong to the monocyte-macrophage linage. J. Immunol., 132, 936, 1984.
33. Zanella A., Mantovani A., Mariani M., Sitvani C , Pen G., Tedesco F. A modified low pH lignocaine method to isolate human monocytes: a comparison with other separation procedures. J. Immunol Methods, 41, 279, 1981.
34. Prass H.F, Maroun J.A. The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods, 68, 235, 1984.